跳至主要内容
临床试验/NCT03709771
NCT03709771终止不适用

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

Vanderbilt University Medical Center1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2020年1月9日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
2
试验地点
1
主要终点
Change in Mean Blood Pressure

研究概览

简要总结

The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female, age 40 - 75 years old
  • Diagnosis of cancer
  • Receiving VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination ICI) treatment, or not receiving any treatment.
  • Normal blood pressure or blood pressure treated to < 140/90 mm Hg with ≤2 antihypertensive medications

排除标准

  • Presence of peripheral artery disease
  • History of a heart attack within 1 year
  • History of a stroke within 1 year
  • Life expectancy < 3 months
  • Women who are pregnant
  • Women who are nursing

结局指标

主要结局

Change in Mean Blood Pressure

时间窗: Baseline and 1 month

Mean 24 hour blood pressure from ambulatory 24 hour recording

次要结局

  • Ratio of Post-treatment to Pre-treatment Change in Digital Pulse Amplitude(Baseline and 1 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Joshua Beckman

Professor

Vanderbilt University Medical Center

研究点 (1)

Loading locations...

相似试验